-
Mashup Score: 9Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) - 19 day(s) ago
SELARSDI is a pproved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of Stelara SELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
Almost 80% of patients with Huntington’s disease (HD) chorea were able to ach ieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4-week Titration Kit for AUSTEDO AUSTEDO remains the only vesicular monoamine transporter 2 (VMAT2) inhibitor available with 3-year data for this progressive condition 1,2 TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS
Source: www.tevausa.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone microspher es (R064766) Additional UZEDY data include a new analysis from the Phase 3 RISE trial reinforcing its efficacy and safety profile in adults with schizophrenia ADVANCE, a global survey study, will also provide real-world findings on LAI utilization from healthcare professionals, caregivers and patients TEL AVIV, Israel & PARSIPPAN
Source: www.tevausa.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate - 1 month(s) ago
Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step in mAbxience’s global expansion strategy and advances a key element of Teva’s Pivot to Growth strategy to expand its biosimilar pipeline through business development Teva-mAbxience partnership reflects the companies’ shared commitment to expand access to critical healthcare solutions to more patients who need them Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective alternatives to existing oncology therapies, thereby addressing a critical need in
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program Development funding agreement to provide up to $150 million to offset program costs and to accelerate clinical research for Teva’s TEV-‘248 program in line with Teva’s Pivot to Growth strategy to step up innovation and advance its innovative pipeline Teva’s TEV-‘248 has the potential to be the first Dual-Action Asthma Rescue Inhaler combining an Inhaled Corticosteroid with a Short-Acting Beta-Agonist (ICS-SABA) for both adult and pediatric asthma indications Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Today Teva announced a clinical collaboration agreement with Launch Therapeutics and a strategic funding development agreement with @Abingworthbio to accelerate development of our dual-action asthma rescue inhaler respiratory program. Read more: https://t.co/0KqB2lyypD #Asthma https://t.co/ZdDurPB4dt
-
-
Mashup Score: 12
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest grossing pharmaceutical products in the world, with sales in the U.S. of
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 7Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting - 3 month(s) ago
Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A (TEV-’574) 1 Anti-TL1A (TEV-’574) was shown to be safe and well-tolerated, with a low incidence of antidrug antibodies 2 Data support the ongoing Phase 2b clinical investigation of anti-TL1A (TEV-’574) in inflammatory bowel disease 3 TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2Teva Reports Growth in Fourth Quarter and Full Year 2023 - 3 month(s) ago
2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO ® – exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY ® – global annual revenues of $435 million, up 16% from 2022; Generics business continues to stabilize, back to revenue growth Q4 2023 and full year 2023 figures include the impact of the $500 million upfront payment received in connection with the collaboration on our anti-TL1A asset Ongoing net debt reduction – reduced to $16.6 billion as of December 31, 2023 Pivot to Growth strategy in action : Teva api Intended divestiture will allow us to focus on our core business strengths and capital allocation towards growth engines and innovation Exclusive collaboration with Sanofi on anti TL1-A (TEV-‘574) entered into in October 2023 Funding agreement with Royalty Pharma on olanzapine LAI (TEV-’749) License agreement with Biolojic
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2023 business results. https://t.co/RZ6UsL39sy Forward-looking statements are subject to the cautionary note included in our Q3 2023 press release. #QuarterlyResults #Earnings $Teva https://t.co/x4OToz7Qx1
-
-
Mashup Score: 2Teva Reports Growth in Fourth Quarter and Full Year 2023 - 3 month(s) ago
2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO ® – exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY ® – global annual revenues of $435 million, up 16% from 2022; Generics business continues to stabilize, back to revenue growth Q4 2023 and full year 2023 figures include the impact of the $500 million upfront payment received in connection with the collaboration on our anti-TL1A asset Ongoing net debt reduction – reduced to $16.6 billion as of December 31, 2023 Pivot to Growth strategy in action : Teva api Intended divestiture will allow us to focus on our core business strengths and capital allocation towards growth engines and innovation Exclusive collaboration with Sanofi on anti TL1-A (TEV-‘574) entered into in October 2023 Funding agreement with Royalty Pharma on olanzapine LAI (TEV-’749) License agreement with Biolojic
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2023 business results. https://t.co/RZ6UsL39sy Forward-looking statements are subject to the cautionary note included in our Q3 2023 press release. #QuarterlyResults #Earnings $Teva https://t.co/x4OToz7Qx1
-
-
Mashup Score: 4Teva Pharmaceutical Industries Ltd. - 42nd Annual J.P. Morgan Healthcare Conference - 4 month(s) ago
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.At Teva Pharmaceutical Industries Ltd.,…
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Tune in today at 8:15am PT (11:15am ET) to hear our presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Teva CEO Richard Francis will discuss Teva's #PivotToGrowth strategy, business performance and plans ahead. Join here: https://t.co/T2WJ5Djq1j #JPM2024 $Teva https://t.co/xX3sd8rl5Y
-
#News: A #biosimilar was approved by the FDA today for #psoriaticarthritis and #plaquepsoriasis. We'reproud to continue providing access to treatments for patients living with inflammatory conditions in partnership with @alvotechpr. https://t.co/MqcfrXMLHE https://t.co/Z8M43b55Hc